secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2026-05-11T20:05:14+00:00
Accession:  0001193125-26-216723
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna reports Q1 net loss $8.6M; cash $522M; positive Phase 1 data for SEP-631
--------------------------------------------------------------------------------

- Revenue from Novo Nordisk collaboration $26.5M; net loss improved to $8.6M from $21.5M YoY.
- Cash $522.1M as of March 31, 2026; expected runway into 2029.
- SEP-631 Phase 1 positive: well tolerated, supports once-daily dosing; Phase 2b in CSU planned H2 2026.
- SEP-479 Phase 1 trial for hypoparathyroidism initiated; data expected late 2026/early 2027.
- CMO Jae Kim departing; successor search initiated; will serve advisory role during transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526216723/0001193125-26-216723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526216723/sepn-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer